Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4Front Ventures Corp.FFNTF · Entity 79616 | Director | January 01, 2021 | January 08, 2021 |
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Director | June 03, 2019 | June 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4Front Ventures Corp.
Report date January 01, 2021 · Filed January 08, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Subordinate Voting SharesSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2021-01-01 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 20,000 F1: These holdings were previously reported on the Form 3 filed January 4, 2021. The sole purpose of this amended Form 3 is to add Exhibit 24, Power of Attorney. |
Filing footnotes · ownership attribution and instrument terms
F1: These holdings were previously reported on the Form 3 filed January 4, 2021. The sole purpose of this amended Form 3 is to add Exhibit 24, Power of Attorney.
Arcadia Biosciences, Inc.
Report date June 03, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2029-06-03 | Direct | 40,835 |
Reported balance
After 2019-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-03 · Grant · Acquired 6,912 · Balance 40,835 F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 3, 2020 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 3, 2020 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 4, 2019 19:50 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 6,912 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034583 · doc4.xml · derivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,835 Underlying: Common Stock · 6,912 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 3, 2020 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 19:38 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 3,204 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001209191-18-036795 · doc4.xml · derivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,923 Underlying: Common Stock · 3,204 shares Expires 2028-06-06 F1 · derivative.exercise_date: The Option will become 100% vested and excercisable on the earlier to occur of (i) June 6, 2019 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:42 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001209191-18-021808 · doc4.xml · derivative · entry 3 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,719 Underlying: Common Stock · 5,000 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully exercisable as of the date hereof. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:42 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | SaleCommon Stock | 5,000 | $33.44 | $167,200.00 |
DisclosureSEC source: 0001209191-18-021808 · doc4.xml · nonDerivative · entry 2 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 F1 · price: This transaction was executed in multiple trades at prices ranging from $32.56 to $34.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:42 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionCommon Stock | 5,000 | $21.60 | $108,000.00 |
DisclosureSEC source: 0001209191-18-021808 · doc4.xml · nonDerivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 250 | $0.00 Strike: $44.88 | $0.00 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · derivative · entry 6 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,719 Underlying: Common Stock · 250 shares Expires 2019-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully exercisable as of the date hereof. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | SaleCommon Stock | 250 | $60.00 | $15,000.00 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · nonDerivative · entry 4 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 F1 · kind: The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan adopted by the Reporting Person effective June 6, 2017. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionCommon Stock | 250 | $44.80 | $11,200.00 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · nonDerivative · entry 3 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 21,005 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · derivative · entry 5 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,969 Underlying: Common Stock · 21,005 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully exercisable as of the date hereof. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | SaleCommon Stock | 21,005 | $45.21 | $949,615.05 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · nonDerivative · entry 2 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 F1 · kind: The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan adopted by the Reporting Person effective June 6, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.00 to $49.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionCommon Stock | 21,005 | $21.60 | $453,708.00 |
DisclosureSEC source: 0001209191-18-020441 · doc4.xml · nonDerivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 13:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 5,000 | $0.75 | $3,750.00 |
DisclosureSEC source: 0001209191-17-039055 · doc4.xml · nonDerivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,680 Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 18:17 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 119,377 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-17-038986 · doc4.xml · derivative · entry 1 Rey Eric J. · CIK 0001640665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,377 Underlying: Common Stock · 119,377 shares Expires 2027-06-07 F1 · shares: The shares subject to the Option shall vest and become exercisable in three (3) equal annual installments, with one-third of the shares subject to the Option vesting on each of the first three (3) anniversaries of the date of the award, subject to the Participant's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.